Diseases and Conditions
Surgical Procedures
Lab Tests
Symptoms
Nutrition
Special Topics
Anatomy Explorer
BMI Calculator
Health IQ
Ready When You Are
Resources
Newsletter Register
Symptom Manager
Video Library
CME
Allergies & Asthma
Arthritis
Back Pain
Bone, Joint & Muscle
Cancer
Diabetes
Eye
Headache
Heart
HIV/AIDS
The New You
Parenting
Womens Health
Alternative Medicine
Before Your Visit
More...
Copyright 1998-2005.
Discovery
Communications Inc.
All Rights Reserved.Privacy Statement
|
FDA Approves Gloucester Pharmaceuticals' ISTODAX(R) For Patients With Cutaneous T-cell Lymphoma
Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The approval of ISTODAX was based on objective disease response defined as the proportion of patients with confirmed complete response or partial response. |
|
